Cargando…

Overview of Molecular Detection Technologies for MET in Lung Cancer

SIMPLE SUMMARY: A variety of MET aberrations that lead to the dysregulation of the MET oncogene and thus the activation of various signaling pathways have been described. These include MET overexpression, the activation of MET mutations comprising exon 14 skipping mutations, MET gene amplifications,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heydt, Carina, Ihle, Michaela Angelika, Merkelbach-Bruse, Sabine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251963/ https://www.ncbi.nlm.nih.gov/pubmed/37296895 http://dx.doi.org/10.3390/cancers15112932

Ejemplares similares

Biomarker MET in der Tumorpathologie
por: Ihle, Michaela Angelika, et al.
Publicado: (2023)

Molecular Characteristics of Radon Associated Lung Cancer Highlights MET Alterations
por: Gamerith, Gabriele, et al.
Publicado: (2022)

MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas
por: Schmitz, Katja, et al.
Publicado: (2015)

Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors
por: Heydt, Carina, et al.
Publicado: (2019)

FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro
por: Künstlinger, Helen, et al.
Publicado: (2015)

Massively parallel sequencing fails to detect minor resistant subclones in tissue samples prior to tyrosine kinase inhibitor therapy
por: Heydt, Carina, et al.
Publicado: (2015)

Comparison of Pre-Analytical FFPE Sample Preparation Methods and Their Impact on Massively Parallel Sequencing in Routine Diagnostics
por: Heydt, Carina, et al.
Publicado: (2014)

Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies
por: Castiglione, Roberta, et al.
Publicado: (2018)

Mutational spectrum of acquired resistance to reversible versus irreversible EGFR tyrosine kinase inhibitors
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2020)

Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies
por: Klein, Sebastian, et al.
Publicado: (2020)

Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations
por: Ihle, Michaela Angelika, et al.
Publicado: (2014)

Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021)

Use of the GeneReader NGS System in a clinical pathology laboratory: a comparative study
por: Koitzsch, Ulrike, et al.
Publicado: (2017)

Mismatch Repair Deficiency and Somatic Mutations in Human Sinonasal Tumors
por: Hieggelke, Lena, et al.
Publicado: (2021)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Genetic instability and recurrent MYC amplification in ALK‐translocated NSCLC: a central role of TP53 mutations
por: Alidousty, Christina, et al.
Publicado: (2018)

Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing
por: Heydt, Carina, et al.
Publicado: (2020)

Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas
por: Helbig, Doris, et al.
Publicado: (2017)

Expression of cell cycle regulators and frequency of TP53 mutations in high risk gastrointestinal stromal tumors prior to adjuvant imatinib treatment
por: Ihle, Michaela Angelika, et al.
Publicado: (2018)

HR23b expression is a potential predictive biomarker for HDAC inhibitor treatment in mesenchymal tumours and is associated with response to vorinostat
por: Angelika Ihle, Michaela, et al.
Publicado: (2016)

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies
por: Scheffler, Matthias, et al.
Publicado: (2014)

qPCR in gastrointestinal stromal tumors: Evaluation of reference genes and expression analysis of KIT and the alternative receptor tyrosine kinases FLT3, CSF1-R, PDGFRB, MET and AXL
por: Fassunke, Jana, et al.
Publicado: (2010)

Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma
por: Quaas, Alexander, et al.
Publicado: (2019)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation
por: Heydt, Carina, et al.
Publicado: (2021)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

CMS Overview of MET Searches
por: Padhi, Sanjay
Publicado: (2011)

ATLAS Overview of MET Searches
por: Bruneliere, Renaud
Publicado: (2011)

Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
por: Kron, A, et al.
Publicado: (2018)

Overview of Ultrasound Detection Technologies for Photoacoustic Imaging
por: Manwar, Rayyan, et al.
Publicado: (2020)

ALK(G1269A) mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor
por: Michels, Sebastian Y. F., et al.
Publicado: (2017)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Met in lung cancer
por: Dent, Paul
Publicado: (2014)

MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations
por: Socinski, Mark A., et al.
Publicado: (2021)

Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer
por: Lv, Huilai, et al.
Publicado: (2015)

Brain Metastases from Lung Cancer: Is MET an Actionable Target?
por: Stella, Giulia M., et al.
Publicado: (2019)

The Molecular Crosstalk between the MET Receptor Tyrosine Kinase and the DNA Damage Response — Biological and Clinical Aspects
por: Medová, Michaela, et al.
Publicado: (2013)

Utility of different massive parallel sequencing platforms for mutation profiling in clinical samples and identification of pitfalls using FFPE tissue
por: FASSUNKE, JANA, et al.
Publicado: (2015)

A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del)
por: Huss, Sebastian, et al.
Publicado: (2013)

Adulteration detection technologies used for halal/kosher food products: an overview
por: Mortas, Mustafa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n0ut3kd8fte3hnq4i0gbpo1g0t